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roteins are macromolecules consisting of different
numbers and sequences of amino acids, which allow
them to adopt different 3D structures and possess
unique biological functions. Among the most im-
portant of these biological functions are biochemical
reaction catalysis, cellular signal generation, ligand transport,
and structural support. The overall protein structure is ﬂexi-
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ABSTRACT:
Five-nanosecond molecular dynamics (MD) simulations
were performed on human serum albumin (HSA) to
study the conformational features of its primary ligand
binding sites (I and II). Additionally, 11 HSA snapshots
were extracted every 0.5 ns to explore the binding afﬁnity
(Kd) of 94 known HSA binding drugs using a blind
docking procedure. MD simulations indicate that there is
considerable ﬂexibility for the protein, including the
known sites I and II. Movements at HSA sites I and II
were evidenced by structural analyses and docking
simulations. The latter enabled the study and analysis of
the HSA–ligand interactions of warfarin and ketoprofen
(ligands binding to sites I and II, respectively) in greater
detail. Our results indicate that the free energy values by
docking (Kd observed) depend upon the conformations of
both HSA and the ligand. The 94 HSA–ligand binding
Kd values, obtained by the docking procedure, were
subjected to a quantitative structure-activity relationship
(QSAR) study by multiple regression analysis. The best
correlation between the observed and QSAR theoretical
(Kd predicted) data was displayed at 2.5 ns. This study
provides evidence that HSA binding sites I and II interact
speciﬁcally with a variety of compounds through
conformational adjustments of the protein structure in
conjunction with ligand conformational adaptation to
these sites. These results serve to explain the high ligand-
promiscuity of HSA. # 2009 Wiley Periodicals, Inc.
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ble under natural conditions. As such, it is possible that regu-
latory proteins have different binding sites and undergo
ligand-binding site conformational changes during the pro-
cess of ligand binding.1 However, it has been shown that
some monomeric proteins are capable of binding to several
ligands at different sites.2 These types of proteins have been
termed ‘‘ligand promiscuous.’’ This behavior is a feature of
human serum albumin (HSA), the most abundant plasma
protein, and is characterized by its surprising capacity to
bind a large variety of biologically active molecules.3
The reason for the high degree of promiscuity of HSA
remains unclear.4 Therefore, promiscuous proteins, such as
HSA and HIV-1 reverse transcriptase, have been the subject
of an intense scientiﬁc debate that is centered around
whether drugs can bind to several protein targets unselec-
tively or in speciﬁc forms.5 It has been proposed that promis-
cuous protein activity, in contrast to nonpromiscuous pro-
teins, is predominantly entropy driven, excluding pair-wise
enthalpy interactions.6 As such, a deeper understanding of
the physiochemical and structural properties of HSA may
serve to better elucidate the behavior of these promiscuous
proteins. It is well known that the formation of a ligand–pro-
tein complex depends on atomic charge, steric hindrance,
and hydrophobic properties.7,8 A recent study demonstrated
that inducing conformational disorder may serve to enhance
drug afﬁnity in the protein-drug association process.9 Thus,
HSA protein movements could permit a degree of plasticity,
which in turn might be directly related to a myriad of func-
tions and binding properties that could be used to design
new protein carriers for drugs.10
During the course of drug design, it is important to fully
understand the conformational barriers involved in the
ligand–target recognition process. Such a task can be
achieved through several techniques, including X-ray crystal-
lography, nuclear magnetic resonance (NMR) spectroscopy,
and scanning electron microscopy (SEM). Additionally, com-
putational methods, such as molecular dynamics (MD) sim-
ulations, can be used. MD is a computational method com-
monly used to generate multiple target conformations, allow-
ing signiﬁcant backbone and amino acid side chain
rearrangements.11,12 It has also been shown that MD yields
better data when mixed with docking simulations that allow
for the visualization of ligand recognition behavior and for
the analysis of free energy values, in comparison with experi-
mental results.13
While X-ray, NMR, and SEM experiments can show
ligand–protein interactions with a high level of molecular
detail, theoretical binding energy calculations by docking
methods can be used to analyze biological processes rapidly
and efﬁciently. These also enable the calculation of molecular
interaction free energy values.14 Molecular docking is widely
used in drug discovery to aid in understanding the molecular
interactions involved in protein–ligand binding. Historically,
docking protocols have considered both the ligand and pro-
tein, in rigid structure form, as adequate representations of
the protein.15 Subsequently, the ligand is treated as a ﬂexible
entity.16 However, this method typically does not take into
account protein side chains, which are generally more disor-
dered than those in the backbone. As a result, ﬂexible target/
ligand models have been proposed where multiple side chain
conformers are generated, while maintaining ﬁxed backbone
atoms.17 Other newer models have introduced a more accu-
rate description by introducing protein ﬂexibility and its
inﬂuence on ligand recognition.18–20
In the present study, MD and docking techniques were
combined to evaluate the binding of 94 different HSA drugs,
which were reported by Colmenarejo et al.21 (see Supporting
Information: Table I-S), on 11 HSA snapshots. These were
extracted every 0.5 ns, during 5 ns of MD simulation, and
were performed using both solvated and ionized HSA condi-
tions. These studies facilitated the evaluation of the contribu-
tion of HSA conformational changes toward its protein
promiscuity. A subset of analyses focused speciﬁcally on pro-
tein–ligand interactions of warfarin and ketoprofen.22 All
docking results were validated by a quantitative structure-
activity relationship (QSAR) performed using the multiple
linear regression modeling method.
MD PROTOCOL
Classical MD simulations were carried out using the NAMD
2.6 program23 using the CHARMM27 force ﬁeld.24 Starting
HSA coordinates were taken from the 1.9 A˚ resolution crystal
structure of Wardell M. et al., (PDB ID: 1n5u).25 The
included heme group, myristic acid, and water molecules of
the crystal structure were removed. Hydrogen atoms were
added by using the psfgen program included in the VMD
package.26 Next, this structure was neutralized with 14 so-
dium ions after being immersed in a TIP3P water box con-
taining 22,604 water molecules. The equilibration protocol
began with 1500 minimization steps followed by 30 ps of
MD at 310 K with ﬁxed protein atoms. Then, the entire sys-
tem was minimized for 1500 steps (at 0 K) and then heated
gradually from 10 to 310 K by temperature reassignment
during the ﬁrst 60 ps of a 100-ps equilibration dynamics,
without restraints.27 The ﬁnal step was a 30 ps NTP dynamics
using the Nose-Hoover Langevin piston pressure control28
at 310 K and 1.01325 bar for density (volume) ﬁtting.
From this point, the simulation was continued in the NTV
ensemble for 5 ns. Periodic boundary conditions and the
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particle-mesh Ewald method29 were applied for a complete
electrostatics calculation. The dielectric water constant was
used, and the temperature was maintained at 310 K using
Langevin dynamics. Nonbonded interactions were calculated
by applying a 10 A˚ cutoff, with a switching function at 8 A˚.
The nonbonded list generation was stopped at 11.5 A˚. The
SHAKE method30 was used to provide an integration time
step of 2 fs, while keeping all bonds to hydrogen atoms rigid.
The trajectory was stored every 1 ps and further analyzed
with the VMD program.26 The MD simulation output over
5 ns provided several HSA structures that were sampled every
0.5 ns (see Figure 1) to study the ligand recognition energetic
and binding modes of 94 well-known ligands.21
DOCKING PROTOCOL
Geometry optimization of the ligands reported by Colme-
narejo21 was performed by HYPERCHEM (Version 7.0,
Hypercube, USA, http://www.hyper.com) at the AM1 level.
The AutoDock (3.0.5) program was selected for docking
studies, as this algorithm maintains a rigid macromolecule
while allowing ligand ﬂexibility.16 This program has been
used widely because it displays good free energy correlation
values between docking simulations (observed) and experi-
mental data.31 This program begins with a ligand molecule
in an arbitrary conformation, orientation, and position. It
identiﬁes the most energetically favorable ligand-HSA com-
plexes by using both simulated annealing and genetic algo-
rithms. A GRID-based procedure was utilized to prepare
structural inputs and to deﬁne all binding sites.32 A rectangu-
lar lattice (126 3 126 3 126 A˚), with points separated by
0.375 A˚, was superimposed on the entire protein structure
following a blind docking procedure.33
All docking simulations were conducted using the hybrid
Lamarckian genetic algorithm, with an initial population of
100 randomly placed individuals and a maximum of 1.0 3
107 energy evaluations. All other parameters were maintained
at their default settings. The resulting docked orientations
within a root mean square deviation of 0.5 A˚ were clustered
together. The lowest energy cluster for each ligand was sub-
FIGURE 1 (A) The a-carbon root mean square distance (RMSD) for HSA during 5 ns of MD
simulations and the time averaged (B) a-carbon and (D) whole RMSD for residues of binding sites
I and II. Comparisons are given in (C) and (E).
Exploration of Human Serum Albumin Binding Sites 163
Biopolymers
jected to further free energy values and binding geometric
analyses, as previously reported.34
MOLECULAR DESCRIPTORS
Chemical structures of the 94 HSA drug and drug-like com-
pounds reported by Colmenarejo21 were obtained from the
National Center for Biotechnology Information (available at:
http://pubchem.ncbi.nlm.nih.gov/search). These structures
were optimized at the AM1 level of semiempirical theory
using the HYPERCHEM software program. The AM1 geom-
etry optimizations were preceded by the Polak-Rebiere algo-
rithm to reach a 0.01 root mean square gradient (298 K, gas
phase). Esbelen (compound number 8, see Supporting Infor-
mation Table I-S) was removed from this set, as selenium
(Se) is not parameterized in the AM1 semiempirical method.
In this study, a set of 60 molcular descriptors was calculated
using the HYPERCHEM and DRAGON software programs
(see Supporting Information Table II-S). These descriptors
include constitutional, topological, chemical, and quantum
descriptors.
QSAR ANALYSIS
QSAR analysis of docking results was performed using multi-
ple linear regression analysis with stepwise selection and
elimination of variables. This was carried out to model the
observed and theoretical binding afﬁnity (log Kd values) rela-
tionships with a set of 60 descriptors. Some compounds were
removed, due to large DG values (unrealistic Kd values), and
other outliers were discarded from the principal component
analysis.4 As such, the relationship analysis between observed
and docking-calculated log Kd values was conducted for a set
of 78 ligands. Multilinear regression models and cross-valida-
tion parameters at different time values (t) are shown in Sup-
porting Information (Figures 1-S and 2-S, Tables III-S and
IV-S), and a key for descriptor abbreviations used in this
study is provided in Supporting Information (Table II-S).
RESULTS AND DISCUSSION
Molecular Dynamic Simulations
In this study, we used combined MD/docking approaches to
estimate the binding afﬁnities of several HSA ligands and
subsequently carried out QSAR analyses using several ligand
properties. The overall goal of the MD simulation was to
provide a more reﬁned and ﬂexible HSA structure model for
use during the docking procedure, as shown by Alonso
et al.35 The procedure was carried out while accounting for
certain physiological and environmental factors that occur
on proteins, which are not considered in simpler docking
protocols.16 This is mainly because 3D protein structures
placed in the Protein Data Bank must be corrected for
unnatural features, such as bad contacts or missing atoms.
Relaxation of the 3D structure is required when using the
solid-state X-ray in order to obtain conformations adequate
for performing the required docking simulations. This can be
achieved by an MD simulation of protein ﬂexibility (see Fig-
ure 2) taking into account conformational changes in the
FIGURE 2 (A) All HSA conformer structures from MD simula-
tions, from 0 to 5 ns in 0.5 ns increments. (B) HSA conformer
structures at 0 and 5 ns. (C) HSA binding sites (I and II) at 0 and 5
ns. In this ﬁgure, the blue coloring5 0 ns and red coloring 5 5 ns.
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binding site region, due to the mobility of its neighboring
protein regions and the intrinsic backbone ﬂexibility of some
amino acid residues.36 It is important to consider this fact
for ligand recognition processes, to improve theoretical bind-
ing energies by computational docking methods. However,
theoretical methods do not consider many factors involved
in ligand–target recognition, which are certainly beyond the
chemical composition of the ligand.
The plot of the backbone a-carbon root mean square dis-
tance (RMSD Ca, Figure 1A) shows a structural transition
during the 5 ns of MD simulation for the whole protein. This
is maintained for the ﬁrst 2 ns, when the RMSD Ca is raised
from 1.3 to 2.5 A˚, reaching 3.0 A˚ at some points during the
remainder of the simulation. It is well known that HSA pos-
sesses two primary ligand binding sites (I and II). These
binding sites have been identiﬁed by X-ray crystallographic
FIGURE 3 Docking interactions of warfarin at site I of all HSA MD snapshots sampled.
Exploration of Human Serum Albumin Binding Sites 165
Biopolymers
analysis, ﬂuorescence, afﬁnity chromatography, calorimetric
analysis, circular dichroism, and other experimental tech-
niques, some of which have yielded ligand–protein afﬁnities.
Sudlow’s nomenclature places site I in HSA subdomain IIA,
where bulky heterocyclic anions prefer to bind, whereas site
II is placed in subdomain IIIA, which is preferred by aro-
matic carboxylates.37,38 To date, two of the most studied
HSA ligands are warfarin and ketoprofen. It is known that
binding site I is selective for warfarin,39 whereas binding site
II is selective for ketoprofen.40,41 The majority of the residues
that comprise both binding sites shows an averaged RMSD
Ca (3 ns) for the entire simulation, as illustrated in Figures
1B and 1C. In the case of binding site I, Ser193, Tyr148,
Gln196, and Lys195 show higher mobilities compared with
the remaining residues (Figures 1B and 1D). Although the
side chain of Tyr148 is relatively far from the binding pocket,
the side chains of Lys199, Arg257, and His242 are in direct
contact with the ligands (see Figure 3). As such, their move-
ments would likely affect the estimated afﬁnities for the
ligands over the time course of the MD simulation. Thus,
these could be direct determinants of the ability of this site to
bind to structurally diverse ligands (see Table I). Apparently,
the residues of binding site II displayed lower mobilities
compared to site I (Figures 1B and 1D). However, this is
untrue, as their entire movement was not different (see
Figures 1C and 1E). Only Asn391 and Leu387 showed an
RMSD Ca. Asn391 and Arg485 (whole residue) averaged
signiﬁcantly higher than other residues, which could be due
to its proximity to the protein surface. This would allow it to
make hydrogen bonding interactions with surrounding water
molecules, except for Leu387. These signiﬁcant structural
movements showed different afﬁnity values with ketoprofen
(Table I).
MD simulations indicate that there is signiﬁcant move-
ment for the protein as a whole (Figure 2A), but little move-
ment at sites I and II, according to structural evaluations
(Figures 2B and 2C). These HSA movements were corrobo-
rated by RMSD Ca deviation at sites I and II (Figures 1C and
1E). Such protein ﬂexibility has been associated with changes
in protein function and ligand binding.42,43 This was
observed for HSA, as several HSA subdomain movements
signiﬁcantly modiﬁed binding site behavior. HSA displayed
several structural movements, but it maintained its 3D struc-
ture (not unfolded) under certain pathologies that alter pH,
ionic properties, and osmotic blood properties. This is likely
due to the great number of disulﬁde Cys-Cys bonds17 pos-
sessed by this protein. Thus, HSA movements are not sufﬁ-
cient to unfold the protein (see Figure 2), reproducing the
environmental behavior of HSA. The results of this work
suggest that HSA ﬂexibility underlies the preferential afﬁnity
for several ligands by this protein, as has been observed for
other known promiscuous proteins, such as CYP450 and
chloroperoxidase.44,45 These MD simulations support the
idea that HSA displays conformational movements that
modify several molecular properties and allow it to bind to
several ligands at different times or even at the same time.46
This supports the notion that the HSA protein is ligand pro-
miscuous, as it shows several binding sites at different time
points within movements that conserve its 3D structure.
Docking
The 11 HSA structures, sampled every 0.5 ns during 5 ns of
MD simulation, were used in docking studies with 94 well-
known ligands, including warfarin39 and ketoprofen.40 These
ligands, in particular, were selected to explore the recognition
behavior for known binding sites I and II, respectively
(Figures 3 and 4). The docking free energy values for each of
the complexes, expressed as an empirical free energy poten-
tial, are shown in Table I for these two compounds. The rela-
tive docking orientations of warfarin with respect to the 11
superimposed structures of HSA binding site I are shown in
Figure 3. A similar picture of the relative orientations of
ketoprofen with respect to the 11 superimposed structures of
HSA binding site II is shown in Figure 4. These ﬁgures high-
light the interdependence of HSA binding site conformation
and ligand orientation. In both ﬁgures, the backbone and
side chain movements of the residues involved in ligand rec-
ognition at different times (ns), with respect to the native
Table I Free Energy (DG) Values of Warfarin and Ketoprofen at



















a Docking values at HSA site II.
b Compound 53 in Table 1-S (Supporting Information).
c Compound 59 in Table 1-S (Supporting Information).
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HSA structure (pdb core, 1N5U), are depicted. As such, it is
evident that both binding sites showed considerable ﬂexibil-
ity despite a signiﬁcantly higher degree of motility for the
remainder of the protein (Figures 2A and 2C).
These HSA domain and binding site movements enable
ligands to adopt different structural binding modes (see
Figures 3 and 4) and, consequently, different free energy val-
ues (Table I). This process is facilitated by changes in the rel-
ative orientations of amino acids at the binding sites. These
subsequently induce changes in local physicochemical prop-
erties, such as hydrophobicity, steric hindrance effects, and
electronic distributions. Therefore, it is not surprising that
the net effect is a modiﬁcation of the ligand afﬁnities toward
proteins and protein–protein interactions.47
Although Sudlow’s classiﬁcation of the binding sites
remains useful,48 some high-afﬁnity drugs do not show spe-
ciﬁc preference for site I or II and could simply be binding to
other regions of the HSA molecule (unpublished data). Site
I, also known as the warfarin binding site, is formed by a
pocket located in subdomain IIA of HSA.38 Site I accepts
FIGURE 4 Docking interactions of ketoprofen at site II of all HSA MD snapshots sampled.
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ligands that have dicarboxylic acids and/or bulky heterocyclic
molecules that are characterized by a negative centrally local-
ized charge. This could be due to the presence of Arg257 and
Lys195/199 residues at this binding site, which confer a par-
tial positive character.49 The docking results shown in Figure
3 indicate that warfarin makes several interactions with these
residues, including: p-cation interactions between aromatic
moieties of the ligand and the Arg/Lys side chain amine
group; hydrogen bonding interactions between the hydroxyl
group of Ser192 and oxygen atoms of warfarin, during snap-
shots taken at 4.5 and 5 ns; and p-p interactions with the
aromatic system of Tyr148, during snapshots taken at 3.5 and
4 ns (see Figure 3).
Binding site II is located in subdomain IIIA of HSA and is
known as the benzodiazepine binding site. In addition, ibu-
profen, diazepam, phenylbutazone, and ketoprofen selectively
bind to this site.50 Ligands bound to site II are characterized
by aromatic moieties and carboxylic acids bearing a negatively
charged carboxylate group at the end of the molecule, away
from a hydrophobic center. As previously reported, binding
site II accepts fewer ligands than site I, which could be because
site II is located in a subdomain that corresponds to a more
unstable protein conformation (see Figure 2A) relative to site
I. As a consequence, this small binding site accepts ligands
that display lower overall afﬁnities, as was identiﬁed for ibu-
profen by displacement of oleic acid.51 This observation is
consistent with our ﬁndings (see Table I). Figure 4 demon-
strates that ketoprofen binds to HSA binding site II through
several p-cation interactions between the basic side chain resi-
due of Arg410, at snapshots taken at 1.5, 2, 2.5, 3.5, 4, and 4.5
ns, and Arg485, at snapshots taken at 3 ns, whereas Lys414, at
snapshots of 1.5, 2, 2.5, 3.5, and 4.5 ns, interacts with the aro-
matic system of ketoprofen. Additionally, p–p interactions
between the aromatic moiety of this ligand and Tyr411 are
also present at snapshots taken at 1 and 2 ns.
Aromatic clusters have been reported to play an impor-
tant role in molecular recognition.52 This behavior can be
corroborated by either experimental procedure or theoretical
simulation. One of these theoretical methodologies involves
docking studies that simulate amino acid side chain move-
ment.18 This procedure does not likely take into considera-
tion the important role that the whole protein movement
plays in the ligand recognition process (see Table I). Figure 2
shows small HSA movements at binding site I, as predicted
by docking simulations. However, there is evidence that these
conformational changes can inﬂuence ligand recognition in
different binding geometries and with different free energies
of binding due to changes in the overall chemical environ-
ment. This indicates that minimum protein movements can
display different binding site properties, allowing several
ligand afﬁnities with the same ligand at different time snap-
shots, as was observed in pyruvate kinase.53
Table I shows how the free energy values of warfarin and
ketoprofen docked in HSA. These free afﬁnity values varied
with the individual protein structure sampled at different
simulation times (5 ns), indicating that the HSA free afﬁnity
values for these ligands depend on both protein and ligand
movements (Figures 2–4). These results are consistent with
the observation that site I is more selective for warfarin,
whereas site II is more selective for ketoprofen, in agreement
with reported data.39,40
MD-QSAR Models of Drug Binding to HSA
Our work uses theoretical methods (docking and MD simu-
lations), but few of these models have been explored for pro-
tein–ligand interaction values.19,20 We carried out a QSAR
study by using the ligand descriptor versus Kd values, which
were obtained by docking simulations (observed), to obtain
the Kd values (predicted). Table IV-S (Supporting Informa-
tion) shows cross-validation parameters for the models
obtained at different t values in the 5 ns range. This table
indicates that the model obtained at t5 2.5 ns had the lowest
relative prediction error, the lowest standard error of predic-
tion, and the lowest predictive residual sum of squares value.
As a result, this QSAR model was selected as optimal relative
to all others. The calibration and cross-validation coefﬁcients
of determination for this model were 0.889 and 0.875,
respectively. This indicates that this model can at least
explain the 88.9% and 87.5% variances in the log Kd for the
calibration and prediction, respectively. Figure 5 shows the
predicted and observed log Kd values, along with their resid-
uals for this model.
The regression equation for this model was provided by:
logKd ¼ 2:230 ð2:906Þ þ 0:207 ð0:199Þ
nCIC 0:008 ð0:018Þ nATþ 0:008 0:002Þ
W 0:023 ð0:011Þ Ref  0:046 ð0:029Þ
nHDon 0:051 ð0:020Þ DMt 8:777 ð5:156Þ
PW2 0:002 ð0:000Þ SMTI 0:035 ð0:032Þ
log P  0:003 ð0:001Þ HF 0:357 ð0:164Þ 32
þ 0:826 ð0:334Þ MNCþ 0:023 ð0:011Þ HE
þ 4:151 ð3:434Þ PW4þ 0:021 ð0:015Þ DMx
þ 0:002 ð0:002Þ ZM2V;
where N 5 78, R2 5 0.889, R2CV 5 0.875, PRESS 5 6.960,
SPRESS 5 0.338, PSE 5 0.299, and RSEP 5 5.090%. Here, N
is the number of compounds, R2 is the coefﬁcient of determi-
nation, R2CV is the cross-validation coefﬁcient of determina-
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tion, PRESS is the predictive residual sum of squares, SPRESS
is the uncertainty of prediction, PSE is the standard error of
prediction, and RSEP is the relative standard error of
prediction.
The above equation shows that the most signiﬁcant descrip-
tor is the topological descriptor PW2 (path\walk-2-randic
shape index), where log Kd is inversely proportional to PW2.
Another signiﬁcant descriptor is PW4 (path\walk-4-randic
shape index), where increasing the PW4 value raises the log Kd
value. This means that a greater ligand surface, in general,
increases the protein surface contact on HSA because of an
increase in the number of interactions. This phenomenon has
been widely described for small-protein interactions.54
CONCLUSIONS
We have demonstrated that the combination of MD and
docking procedures provides the best ﬁt for protein–ligand
complexes. This was corroborated and validated with subse-
quent QSAR studies. The results of this study indicate that
HSA movements play an important role in drug recognition.
Although conformational changes were minimal at HSA
binding sites I and II, docked warfarin and ketoprofen dis-
played signiﬁcantly different interactions. As such, this
approach was able to identify the HSA structures involved in
the recognition process and explains HSA promiscuity. In
addition, this study has also facilitated the identiﬁcation of
chemical property changes on several HSA structures that
resulted in different docking energy afﬁnities.
This study illustrates that molecular docking/dynamics
can provide a useful and accurate picture of protein–ligand
interactions at the molecular level. This is because MD
mimics certain key physiological conditions including pH,
ion content, solvation, and temperature. As such, it is a good
option in studying and explaining the molecular basis of si-
multaneous protein recognition selectivity. These computa-
tional techniques can also explain the molecular basis of
pharmacologically important events that involve binding site
recognition on HSA sites II and I in drug displacement.
The authors thank Ian Ilizaliturri Flores for building and supporting
two clusters (6 and 20 nodes) used in the MD and docking simula-
tions at ESM-IPN.
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